SCHEMBL20915856

SCHEMBL20915856

CCC(C)(C)C(=O)On1cc(-c2ccc(N)c(Cl)c2)nn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.34
TSHR P16473 3/20 0.33
ALDH1A1 P00352 2/20 0.33
MAPK1 P28482 2/20 0.33
CYP3A4 P08684 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
ESR2 Q92731 1/20 0.33
ESRRG P62508 1/20 0.32
S1PR1 P21453 3/20 0.31
CHRM3 P20309 1/20 0.31
CDC7 O00311 1/20 0.31
CYP2D6 P10635 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31
RIPK2 O43353 1/20 0.31
MAP3K14 Q99558 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20915839 0.88 NR1H4 (0.31) NR1H4TSHRNPC1LMNAPOLB
SCHEMBL20915646 0.87 SRC (0.35) NR1H4
SCHEMBL20915678 0.85 AR (0.34) NR1H4S1PR1
SCHEMBL20915750 0.80 HSP90AA1 (0.33) NR1H4CHRM3
SCHEMBL20915835 0.79 NR1H4 (0.31) NR1H4
SCHEMBL20915873 0.77 HSP90AA1 (0.31)
SCHEMBL20915855 0.76 CDC7 (0.41) NR1H4NPC1RAB9AESRRGCDC7
SCHEMBL20915724 0.76 NR1H4 (0.30) NR1H4
SCHEMBL14775198 0.68 BCHE (0.32)
Hydrochloric Acid SCHEMBL28632362 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481819-B1 COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS ACQUIST LLC (US) 2022-06-01 EP disclosed
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2021-08-05 US disclosed
US-11020397-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-06-01 US disclosed
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2020-08-27 US disclosed
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC 2020-06-25 US disclosed
US-10688095-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-06-23 US disclosed
US-20190117654-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2019-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10688095-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 NR1H4 821/4885TSHR 2010/4885ALDH1A1 95/4885
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 NR1H4 1085/4885TSHR 2953/4885ALDH1A1 226/4885
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 NR1H4 1085/4885TSHR 2953/4885ALDH1A1 226/4885
US-11020397-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 NR1H4 821/4885TSHR 2010/4885ALDH1A1 95/4885
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 NR1H4 1085/4885TSHR 2953/4885ALDH1A1 226/4885
US-20190117654-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 NR1H4 1085/4885TSHR 2953/4885ALDH1A1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.